Results (4189)
Emulation of a phase 3 study comparing Rituximab with Dimethyl Fumarate in early Relapsing-Remitting Multiple Sclerosis
Sweden
EU PAS number:
EUPAS1000000450
First published:
22/01/2025
StudyOngoing
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) (HALO)
Brazil
Canada
Czechia
France
Germany
Italy
Netherlands
Poland
Spain
United Kingdom
United States
EU PAS number:
EUPAS49827
First published:
22/01/2025
StudyPlanned
TAK-555-4006: A Breast Milk Study in Lactating Women Who Have Been Prescribed Therapeutic Doses of MOTEGRITY® (prucalopride) for Chronic Idiopathic Constipation to Evaluate Prucalopride Concentrations in Breast Milk, and to Collect Incidental Safety Data from the Nursing Infant
United States
EU PAS number:
EUPAS40105
First published:
22/01/2025
StudyOngoing
Vedolizumab-4020: A Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Safety and Efficacy of Vedolizumab in Indian Patients With Ulcerative Colitis and Crohn’s Disease
India
EU PAS number:
EUPAS23702
First published:
22/01/2025
StudyFinalised
Characterization of neurodevelopmental disorders in children exposed in utero to valproate and/or other antiepileptic drugs with long-term follow-up: retrospective study of multiple European data sources (AVALON)
Denmark
Finland
France
Netherlands
Norway
Sweden
United Kingdom
EU PAS number:
EUPAS103711
First published:
22/01/2025
StudyOngoing
Machine learning prediction of anemia events before and after talazoparib dose modification using TALAPRO-2 phase 3 trial data
United States
EU PAS number:
EUPAS1000000344
First published:
22/01/2025
StudyOngoing
A post-authorization safety study (PASS) to evaluate the paternal exposure to valproate and the risk of neurodevelopmental disorders including autism spectrum disorders as well as congenital abnormalities in offspring - a population-based retrospective study
Denmark
Norway
Sweden
EU PAS number:
EUPAS34201
First published:
22/01/2025
StudyFinalised
Assessment of risk factors for Myocarditis in the United States (US) using Electronic Health Records and Claims data
United States
EU PAS number:
EUPAS104403
First published:
22/01/2025
StudyOngoing
Real-world treatment patterns and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line (1L) axitinib + pembrolizumab therapy
United States
EU PAS number:
EUPAS1000000104
First published:
22/01/2025
StudyOngoing
Risk of Safety Events Among Patients with UC and PsA Treated with Tofacitinib and Other Advanced Treatments in the United States
United States
EU PAS number:
EUPAS103443
First published:
22/01/2025
StudyOngoing
A standing cohort to understand the characteristics of patients with COVID-19 and contextualize the COVID-19 complication and safety events of interests using US OPTUM EHR data
United States
EU PAS number:
EUPAS48654
First published:
22/01/2025
StudyOngoing
Uveitis in chronic inflammatory conditions and ulcerative colitis-related pyoderma gangrenosum and axial spondylarthritis: an observational study of patients receiving advanced therapies in the United States
United States
EU PAS number:
EUPAS107604
First published:
22/01/2025
StudyOngoing
A network meta-analysis of real-world studies comparing tofacitinib with other advanced therapies in the treatment of moderate-to-severe ulcerative colitis
United States
EU PAS number:
EUPAS108141
First published:
22/01/2025
StudyOngoing
The European HBV Registry: A joint initiative of TherVacB and DZIF (HBV Registry)
Germany
Italy
Spain
United Kingdom
EU PAS number:
EUPAS42767
First published:
21/01/2025
StudyOngoing
A non-interventional study to assess the long-term safety and efficacy of osilodrostat in patients with endogenous Cushing’s syndrome (LINC 6)
France
Germany
Italy
United States
EU PAS number:
EUPAS46496
First published:
21/01/2025
StudyOngoing
Danish Health Data Registries
First published:
21/01/2025
Denmark
Data source
Human
Cancer registryDrug registryOtherPopulation registryLongitudinal drug utilisation study of the off- label use of tolperisone-containing products in selected EU Member States between 01 January 2019 and 31 December 2023 (HUXX-NIS-TOLPERISONE-01/2024)
Czechia
Poland
Romania
Slovakia
EU PAS number:
EUPAS1000000447
First published:
20/01/2025
StudyFinalised
Non-interventional cohort registry study to assess characteristics and management of patients with Merkel Cell Carcinoma in Germany (MCC-TRIM)
Germany
EU PAS number:
EUPAS25338
First published:
20/01/2025
StudyFinalised
Pergoveris patients’ profile and outcome response measurement in IVF/ICSI autologous cycles (PERFORM)
France
Germany
Greece
Italy
Norway
Romania
Spain
Switzerland
EU PAS number:
EUPAS1000000435
First published:
20/01/2025
StudyOngoing
A Multi-country, Non-interventional, Retrospective Drug Utilization Study in Haematological Malignancy Patients Treated for Probable or Proven Invasive Aspergillosis (AmBiVor)
Belgium
France
Germany
Spain
United Kingdom
EU PAS number:
EUPAS104818
First published:
20/01/2025
StudyOngoing
An Observational Study Assessing the Long-term Risk of Non-Melanoma Skin Cancer (NMSC) Among New Users of OpzeluraTM (Ruxolitinib) Cream in a Vitiligo Patient Population: Post-Authorization Safety Study (PASS)
France
Germany
United States
EU PAS number:
EUPAS1000000413
First published:
20/01/2025
StudyPlanned
Multicenter Observational study to evaluate the effectiveness of a biosimilar Etanercept (ErelziTM) in patients with established Rheumatic disease previously treated with reference etanercept. (BRONZE)
France
EU PAS number:
EUPAS28777
First published:
20/01/2025
StudyFinalised
Clinical Practice Research Datalink
First published:
17/01/2025
United Kingdom
Data source
Human
Birth registryHospital discharge recordsOtherPrimary care medical recordsNorwegian Linked Health registry at University of Oslo, Pregnancy cohort
First published:
17/01/2025
Norway
Data source
Human
Birth registryHospital inpatient recordsHospital outpatient visit recordsPharmacy dispensing recordsPrimary care medical recordsClinical Practice Research Datalink (CPRD)
United Kingdom
First published:
17/01/2025
InstitutionLaboratory/Research/Testing facilityENCePP partner
DARWIN EU® - Association of venous thromboembolism with non-steroidal anti-inflammatory drug use in women 15-49 years using hormonal contraceptives
Denmark
Norway
Spain
United Kingdom
EU PAS number:
EUPAS1000000443
First published:
16/01/2025
StudyOngoing
Post-authorisation safety study to assess the risk of urinary tract malignancies in relation to empagliflozin exposure in patients with type 2 diabetes: a multi-database European study (PASS DiabCancer)
Finland
Sweden
United Kingdom
EU PAS number:
EUPAS16424
First published:
16/01/2025
StudyOngoing
Characterize infections and outcomes developed in relapsed/refractory multiple myeloma (RRMM) patients treated with Teclistamab (SPOT)
Portugal
EU PAS number:
EUPAS1000000414
First published:
16/01/2025
StudyPlanned
NHTA ApS/ AB
Denmark
Sweden
First published:
15/01/2025
InstitutionNon-Pharmaceutical companyENCePP partner
VAG-4602: Vaginal estradiol tablets (Vagifem®) and endometrial cancer risk in the treatment of postmenopausal vaginal atrophy: A register-based cohort study in postmenopausal women
Denmark
United States
EU PAS number:
EUPAS44951
First published:
15/01/2025
StudyFinalised
Norwegian Linked Health registry at University of Oslo
First published:
15/01/2025
Norway
Data source
Human
Birth registryDeath registryDisease registryHospital inpatient recordsHospital outpatient visit recordsPharmacy dispensing recordsPopulation registryPrimary care medical recordsVaccination registryMavacamten Real-World Safety: a post-authorisation multi-national, long-term, observational study in patients with obstructive Hypertrophic Cardiomyopathy (oHCM) in the real-world setting in Europe (CV027-013)
Denmark
France
Germany
Sweden
United Kingdom
EU PAS number:
EUPAS108178
First published:
15/01/2025
StudyPlanned
A long-term observational study to describe the use of PASCORBIN® 7.5 g in patients with vitamin C deficiency. (Long-term OBS PASCORB® 7.5 g)
Germany
EU PAS number:
EUPAS3658
First published:
15/01/2025
StudyOngoing
A Post-marketing, Observational Safety Study of Quinsair (Levofloxacin Hemihydrate) in Patients with Cystic Fibrosis [CLI-LEVFLAA1-01]
Germany
United Kingdom
EU PAS number:
EUPAS20990
First published:
15/01/2025
StudyOngoing
Long-term real-world safety of ozanimod – A post-authorisation safety study (PASS) in patients diagnosed with ulcerative colitis
Denmark
France
Germany
Netherlands
Norway
United Kingdom
EU PAS number:
EUPAS1000000034
First published:
15/01/2025
StudyOngoing
DARWIN EU® – Incidence rates of venous thromboembolic events in patients with selected cancers
Belgium
Denmark
Estonia
Finland
Germany
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS1000000440
First published:
15/01/2025
StudyOngoing
DARWIN EU® Monitoring prescription of essential medicines administered in ICU
France
Portugal
Spain
EU PAS number:
EUPAS1000000089
First published:
15/01/2025
StudyFinalised
PROTECT
Belgium
Denmark
France
Germany
Italy
Netherlands
Poland
Spain
Sweden
Switzerland
United Kingdom
First published:
14/01/2025
Network